SCHEMBL6013236

SCHEMBL6013236

C=CC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 1/20 0.75
ALDH5A1 P51649 1/20 0.59
ABAT P80404 1/20 0.59
SMN1; SMN2 Q16637 5/20 0.55
MAPT P10636 4/20 0.55
ALDH1A1 P00352 4/20 0.55
HPGD P15428 3/20 0.55
ALOX12 P18054 3/20 0.55
MAPK1 P28482 3/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
TDP1 Q9NUW8 2/20 0.55
KDM4E B2RXH2 1/20 0.55
EGFR P00533 1/20 0.55
TP53 P04637 1/20 0.55
CYP3A4 P08684 1/20 0.55
PKM P14618 1/20 0.55
ALOX15 P16050 1/20 0.55
JAK1 P23458 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Biphenyl SCHEMBL5090009 0.92 AKT1 (0.69) AKT1ALDH5A1ABATSMN1; SMN2MAPT
SCHEMBL4315033 0.91 ALDH5A1 (0.70) AKT1ALDH5A1ABATSMN1; SMN2MAPT
SCHEMBL38134 0.86 AKT1 (1.00) AKT1ALDH5A1ABATSMN1; SMN2MAPT
Benzene SCHEMBL27516217 0.86 AKT1 (1.00) AKT1ALDH5A1ABATSMN1; SMN2MAPT
Formaldehyde SCHEMBL27801880 0.84 AKT1 (0.95) AKT1ALDH5A1ABATSMN1; SMN2MAPT
Methane SCHEMBL27566869 0.84 AKT1 (0.95) AKT1ALDH5A1ABATSMN1; SMN2MAPT
Ammonia Solution, Strong SCHEMBL6567239 0.84 AKT1 (0.95) AKT1ALDH5A1ABATSMN1; SMN2MAPT
Fluoride SCHEMBL27784734 0.84 AKT1 (0.95) AKT1ALDH5A1ABATSMN1; SMN2MAPT
Ethylene SCHEMBL27565387 0.84 AKT1 (0.95) AKT1ALDH5A1ABATSMN1; SMN2MAPT
SCHEMBL902533 0.84 KMO (0.62) AKT1ALDH5A1ABATLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105274-B2 Photoluminescent ethylene sensors WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2006-09-12 US claimed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed
US-8937091-B2 Inhibitor of protein crosslinking and use of the same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2015-01-20 US disclosed
US-8937091-B2 Inhibitor of protein crosslinking and use of the same JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2015-01-20 US disclosed
US-8613985-B2 Liquid crystal/polymer composite KABUSHIKI KAISHA TOSHIBA (JP) 2013-12-24 US disclosed
US-20120307184-A1 LIQUID CRYSTAL/POLYMER COMPOSITE KABUSHIKI KAISHA TOSHIBA (JP) 2012-12-06 US disclosed
US-20120277423-A1 PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME JAPAN SCIENCE AND TECHNOLOGY AGENCY 2012-11-01 US disclosed
US-20120277423-A1 PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME JAPAN SCIENCE AND TECHNOLOGY AGENCY 2012-11-01 US disclosed
US-7803822-B2 Triazole derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-28 US disclosed
US-20090105253-A1 Triazole Derivative and Use Thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-23 US disclosed
US-7105274-B2 Photoluminescent ethylene sensors WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2006-09-12 US disclosed
US-20050031985-A1 Photoluminescent ethylene sensors NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2005-02-10 US disclosed
EP-0885869-A1 THERAPEUTIC AGENT FOR DIABETES Japan Tobacco Inc. (JP) 1998-12-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105253-A1 Triazole Derivative and Use Thereof F2R, HRH4, F2RL3 AKT1 2272/4885ALDH5A1 4016/4885ABAT 4525/4885
US-20120277423-A1 PROTEIN CROSSLINKING INHIBITOR AND USE OF THE SAME ARGLU1, F12, CDKL1 AKT1 1984/4885ALDH5A1 3620/4885ABAT 863/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.